Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL201 + Serplulimab vs Carboplatin + Etoposide + Serplulimab in 1L ES-SCLC
NCT07739758Phase 3Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Aug 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 3 trial of YL201 in small cell lung cancer (SCLC), sponsored by MediLink Therapeutics. Started Aug 2026; status: recruiting.
02
Drugs
YL201
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07739758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07739758.